StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Cosentyx (secukinumab by Quarter

Cosentyx (secukinumab — psoriasis, psoriatic arthritis, ankylosing spondylitis & HS) ($M)

QuarterlyAnnual

Novartis Cosentyx (secukinumab: $1,857M in Q3 2026, up 9.4% from a year earlier. That is the highest of the 35 quarters on record here.

Latest, Q3 2026
1,857
Period ended Sep 30, 2026
Change on a year earlier
+9.4%
1,698 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
29
Documents cited below

Where the Q3 2026 figure comes from

“|| Cosentyx | 1 857 | 1 698 | 9 | 9”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCosentyx (secukinumab — psoriasis, psoriatic arthritis, ankylosing spondylitis & HS) ($M)Year on yearSource
Q3 2026Sep 30, 20261,857+9.4%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20261,824+12.0%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 20261,566+2.1%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 20251,807+13.2%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 20251,698+0.3%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 20251,629+6.7%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 20251,534+15.7%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 20241,596+22.5%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 20241,693+27.4%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 20241,526+20.0%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 20241,326+23.2%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 20231,303+20.6%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 20231,329+4.3%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 20231,272-0.2%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 20231,076-7.2%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 20221,080-13.1%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up cosentyx (secukinumab

Cite this data

StockData. (2026). Novartis Cosentyx (secukinumab ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-cosentyx

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.